A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine.

Scope of the Report:

The global Gastrointestinal Stromal Tumors (GISTs) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gastrointestinal Stromal Tumors (GISTs) Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

This report studies the Gastrointestinal Stromal Tumors (GISTs) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gastrointestinal Stromal Tumors (GISTs) Treatment market by product type and applications/end industries.

Market Segment by Companies, this report covers

Pfizer

Bayer

Novartis

Immunicum

Roche

AB Science

Arog Pharmaceuticals

Boston Biomedical

Sun Pharmaceutical

Natco Pharma

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Surgery

Targeted Therapy

Radiation Therapy

Chemotherapy

Ablation

Embolization

Others

Market Segment by Applications, can be divided into

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Table of Contents

1 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Overview

1.1 Product Overview and Scope of Gastrointestinal Stromal Tumors (GISTs) Treatment

1.2 Classification of Gastrointestinal Stromal Tumors (GISTs) Treatment by Types

1.2.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Types in 2017

1.2.3 Surgery

1.2.4 Targeted Therapy

1.2.5 Radiation Therapy

1.2.6 Chemotherapy

1.2.7 Ablation

1.2.8 Embolization

1.2.9 Others

1.3 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market by Application

1.3.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Others

1.4 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market by Regions

1.4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gastrointestinal Stromal Tumors (GISTs) Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Gastrointestinal Stromal Tumors (GISTs) Treatment (2013-2023)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 Bayer

2.2.1 Business Overview

2.2.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Bayer Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 Novartis

2.3.1 Business Overview

2.3.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Novartis Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Immunicum

2.4.1 Business Overview

2.4.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Immunicum Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 Roche

2.5.1 Business Overview

2.5.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Roche Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 AB Science

2.6.1 Business Overview

2.6.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 AB Science Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.7 Arog Pharmaceuticals

2.7.1 Business Overview

2.7.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.8 Boston Biomedical

2.8.1 Business Overview

2.8.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.9 Sun Pharmaceutical

2.9.1 Business Overview

2.9.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.10 Natco Pharma

2.10.1 Business Overview

2.10.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Competition, by Players

3.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Gastrointestinal Stromal Tumors (GISTs) Treatment Players Market Share

3.2.2 Top 10 Gastrointestinal Stromal Tumors (GISTs) Treatment Players Market Share

3.3 Market Competition Trend

4 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size by Regions

4.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Market Share by Regions

4.2 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

5 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries

5.1 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2013-2018)

5.2 USA Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

6 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries

6.1 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2013-2018)

6.2 Germany Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

6.4 France Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries

7.1 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2013-2018)

7.2 China Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

7.5 India Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

8 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries

8.1 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2013-2018)

8.2 Brazil Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Gastrointestinal Stromal Tumors (GISTs) Treatment by Countries

9.1 Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Growth Rate (2013-2018)

10 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Segment by Type

10.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Type (2018-2023)

10.3 Surgery Revenue Growth Rate (2013-2023)

10.4 Targeted Therapy Revenue Growth Rate (2013-2023)

10.5 Radiation Therapy Revenue Growth Rate (2013-2023)

10.6 Chemotherapy Revenue Growth Rate (2013-2023)

10.7 Ablation Revenue Growth Rate (2013-2023)

10.8 Embolization Revenue Growth Rate (2013-2023)

10.9 Others Revenue Growth Rate (2013-2023)

11 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Segment by Application

11.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Share by Application (2013-2018)

11.2 Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)

11.6 Others Revenue Growth (2013-2018)

12 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size Forecast (2018-2023)

12.1 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Size Forecast (2018-2023)

12.2 Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market Forecast by Regions (2018-2023)

12.3 North America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2018-2023)

12.6 South America Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Gastrointestinal Stromal Tumors (GISTs) Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Gastrointestinal Stromal Tumors (GISTs) Treatment Picture

Table Product Specifications of Gastrointestinal Stromal Tumors (GISTs) Treatment

Table Global Gastrointest